top of page


Onco-Summaries: Daily Oncology Updates at a Glance
15/05/2025 Another TIGIT agent fails as iTeos and GSK terminate the belrestotug development program based on disappointing NSCLC and...
Oncofocus Team
May 152 min read
4


Onco-Summaries: Daily Oncology Updates at a Glance
29/04/2025 ALX Oncology’s Phase 2 ASPEN-03 & ASPEN-04 trials failed to meet the primary endpoint of ORR ( Ref 1 ) ALX Oncology hit with a...
Oncofocus Team
Apr 292 min read
8


Onco-Summaries: Daily Oncology Updates at a Glance
24/04/2025 Ivonescimab Plus Chemotherapy Shows Statistically Significant Superiority Over Tislelizumab in First-Line Treatment of...
Oncofocus Team
Apr 242 min read
18


CGT Watch Newsletter: March'25 Edition
Dear Readers, Welcome to our inaugural CGT Watch newsletter! We’re excited to bring you monthly highlights on novel targets, innovative...
Oncofocus Team
Mar 206 min read
8


Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics?
“The right target, at the right time, for the right price” …is and always has been a guiding principle for Merck KGaA, as stated by its...
Oncofocus Team
Feb 112 min read
21


FOUR Pivotal Trials Could Redefine The First-Line Melanoma Treatment Landscape in 2025
The first-line metastatic Melanoma market is currently dominated by immune checkpoint inhibitors—BMS' Opdivo + Yervoy, Opdualag, Opdivo,...
Oncofocus Team
Feb 73 min read
38
bottom of page